The oncological biopharmaceutical research company is looking to raise up to $50m from an initial public offering less than 18 months after its inception.
US-based biopharmaceutical company Verastem filed for an initial public offering (IPO) with the US Securities & Exchanges Commission on Thursday, which could raise up to $50m.
The chief shareholders in Verastem include venture capital (VC) firm Longwood Founders Fund which owns 15.5% of Verastem, VC firm Bessemer Venture Partners and VC partnership Cardinal Partners which each own 13.5%, private equity investor MPM Bioventures which owns 13.2%, and VC firm Advanced Technology Ventures which owns 5.1%. Longwood was founded by…
